TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19139846

Group type: EXPERIMENTAL
Intervention: Cruciate retaining implants
Number of subjects: 101
Study: 16930699

Group type: EXPERIMENTAL
Intervention: ARC organizational intervention
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 26
Study: 15253862

Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 11767219

Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 74

Group type: COMPARATOR
Intervention: Serial antenatal foetal monitoring
Number of subjects: 74
Study: 9253908

Group type: EXPERIMENTAL
Intervention: Standard fat emulsion dose (L)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Withholding fat infusions (NL)
Number of subjects: 57
Study: 8490316

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg for induction)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Thiopental (4 mg/kg for induction)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg after intubation)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Thiopental (2 mg/kg after intubation)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 28
Study: 3539256

Group type: EXPERIMENTAL
Intervention: Intraperitoneal drain
Number of subjects: 112

Group type: COMPARATOR
Intervention: No drain (non-drainage group)
Number of subjects: 112
Study: 28865169

Group type: EXPERIMENTAL
Intervention: Motivational intervention (EA-MI)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 226
Study: 27185372

Group type: EXPERIMENTAL
Intervention: 250 mg fulvestrant
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 500 mg fulvestrant
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Fulvestrant (both dosages)
Number of subjects: 134
Study: 24091594

Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (3 mg quarterly)
Number of subjects: 6064

Group type: COMPARATOR
Intervention: Oral alendronate (70 mg weekly)
Number of subjects: 6064
Study: 22302780

Group type: EXPERIMENTAL
Intervention: STAR educational programme
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 68
Study: 20536646

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 or 90 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17803701

Group type: EXPERIMENTAL
Intervention: PCOS women
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study: 15844503

Group type: EXPERIMENTAL
Intervention: Radiologists using criteria of important mucosal swelling, air-fluid level or complete opacity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Radiologists using criteria of air-fluid level or complete opacity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ENT surgeons using criteria of important mucosal swelling, air-fluid level or complete opacity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ENT surgeons using criteria of air-fluid level or complete opacity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: General practitioners using criteria of important mucosal swelling, air-fluid level or complete opacity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: General practitioners using criteria of air-fluid level or complete opacity
Number of subjects: 80
Study: 12885819

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL) assessments in RCTs
Number of subjects: 8445
Study: 11249411

Group type: EXPERIMENTAL
Intervention: Cotton cover gowns
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cotton cover gowns (Control)
Number of subjects: 0
Study: 8879436

Group type: EXPERIMENTAL
Intervention: Oestradiol (2 mg/day) alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oestradiol (2 mg/day) with norethisterone (1 mg/day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oestradiol (2 mg/day) alone (sub-set of 32 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oestradiol/norethisterone (1 mg/day)
Number of subjects: 80
Study: 1994666

Group type: EXPERIMENTAL
Intervention: MRI (Spin Echo, multislice‐multiphase technique on the short‐axis plane)
Number of subjects: 32
Study: 6723349

Group type: EXPERIMENTAL
Intervention: Controlled-release formulation of ketoprofen (2 capsules of 100 mg once daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional capsule formulation of ketoprofen (100 mg capsules twice daily)
Number of subjects: 46
Study: 30409490

Group type: EXPERIMENTAL
Intervention: Bevacizumab with pegylated liposomal doxorubicin (PLD)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Bevacizumab with topotecan
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Bevacizumab with weekly paclitaxel
Number of subjects: 391

Group type: COMPARATOR
Intervention: Weekly paclitaxel
Number of subjects: 391

Group type: COMPARATOR
Intervention: PLD
Number of subjects: 391
Study: 30377220

Group type: EXPERIMENTAL
Intervention: Inpatient tobacco cessation and exposure reduction program for parents of hospitalized children, including education about resources like the Colorado QuitLine.
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Educational interventions for clinical staff regarding smoking cessation resources.
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Educational interventions regarding hospital cessation resources.
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Support for free nicotine replacement therapy.
Number of subjects: 192
Study: 25619495

Group type: EXPERIMENTAL
Intervention: Modified algorithm for lymph node sampling
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Standardized sonographic classification system
Number of subjects: 1051
Study: 24589124

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 500

Group type: COMPARATOR
Intervention: Atosiban
Number of subjects: 500
Study: 23273213

Group type: EXPERIMENTAL
Intervention: Multidisciplinary pain programme with minimal interventional procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multidisciplinary pain programme alone
Number of subjects: 0
Study: 20452382

Group type: EXPERIMENTAL
Intervention: Familiar faces (Familiar)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Unfamiliar faces (Other)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Novel faces (Novels)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Behavioral test of face memory
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Early-stage facial identity processing
Number of subjects: 29
Study: 17346807

Group type: EXPERIMENTAL
Intervention: Regular desloratadine treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: On-demand desloratadine treatment
Number of subjects: 37
Study: 16193613

Group type: EXPERIMENTAL
Intervention: Information leaflet
Number of subjects: 1024

Group type: COMPARATOR
Intervention: No leaflet (Control)
Number of subjects: 1024
Study: 12972521

Group type: EXPERIMENTAL
Intervention: EC plus LND (B group)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: EC plus G-CSF (C group)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: EC plus LND plus G-CSF (D group)
Number of subjects: 506

Group type: COMPARATOR
Intervention: EC alone (A group)
Number of subjects: 506
Study: 10759819

Group type: EXPERIMENTAL
Intervention: High-intensity continuous wave ultrasound (3 W/cm2, 1 MHz for 10 minutes)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Extremely low-intensity ultrasound (placebo, 0.3 W/cm2, 1 MHz for 10 minutes)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-intensity continuous wave ultrasound
Number of subjects: 19

Group type: COMPARATOR
Intervention: Extremely low-intensity ultrasound (placebo)
Number of subjects: 19
Study: 8674092

Group type: EXPERIMENTAL
Intervention: Propafenone 600 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (Control Group A)
Number of subjects: 30
Study: 1985380

Group type: EXPERIMENTAL
Intervention: Short-to-long protocol
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 77
Study: 6628707

Group type: EXPERIMENTAL
Intervention: 1.0 mg dl-norgestrel and 0.1 mg ethinylestradiol administered orally at 18 hours after LH rise and again at 30 hours
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (placebo) cycle
Number of subjects: 5
Study: 31838462

Group type: EXPERIMENTAL
Intervention: Morning carbohydrate-restriction diet (MCR-D)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Mediterranean diet (Med-D)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 70
Study: 30678759

Group type: EXPERIMENTAL
Intervention: Adverse plaque characteristics (positive remodeling or low attenuation plaque)
Number of subjects: 1769

Group type: EXPERIMENTAL
Intervention: Obstructive disease
Number of subjects: 1769

Group type: EXPERIMENTAL
Intervention: Both obstructive disease and adverse plaque
Number of subjects: 1769

Group type: COMPARATOR
Intervention: Normal coronary arteries
Number of subjects: 1769
Study: 28247479

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (LPV/r)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 16
Study: 25132248

Group type: EXPERIMENTAL
Intervention: Interleukin-8 (IL-8)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Neutrophils
Number of subjects: 811
Study: 24091849

Group type: EXPERIMENTAL
Intervention: Cisplatin + Paclitaxel (TP) 45 mg/m²/week
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cisplatin + Docetaxel (DP) 20 mg/m²/week
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cisplatin + Gemcitabine (GP) 350 mg/m²/week
Number of subjects: 93
Study: 21840467

Group type: EXPERIMENTAL
Intervention: AquADEKs chewable tablets
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AquADEKs capsules
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AquADEKs liquid
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vitamins A (3 mg daily), E (200 mg daily), and D(3) (20 μg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (healthy children)
Number of subjects: 50
Study: 19646229

Group type: EXPERIMENTAL
Intervention: CPR training (6 hours)
Number of subjects: 147
Study: 17192960

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 254

Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: SVG patients
Number of subjects: 254

Group type: COMPARATOR
Intervention: Non-SVG patients
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Thrombus presence
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Lesion length > 20 mm
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Thrombolysis in myocardial infarction flow < 3 post-procedure
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: >1 target lesion
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Eccentricity
Number of subjects: 254
Study: 15097304

Group type: EXPERIMENTAL
Intervention: Enrollment in the preventive HIV vaccine trial
Number of subjects: 2531

Group type: EXPERIMENTAL
Intervention: Hypothetical willingness to enroll
Number of subjects: 2531

Group type: EXPERIMENTAL
Intervention: Demographic factors affecting enrollment
Number of subjects: 2531

Group type: EXPERIMENTAL
Intervention: Concerns about vaccine-induced seropositivity
Number of subjects: 2531

Group type: EXPERIMENTAL
Intervention: Barriers to enrollment for African Americans
Number of subjects: 2531
Study: 11736674

Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Isoflurane anaesthesia
Number of subjects: 26
Study: 9434921

Group type: EXPERIMENTAL
Intervention: Antithrombin III concentrate to achieve 100% activity (n=10)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Antithrombin III concentrate to achieve 175% activity (n=9)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group received saline 0.9% (n=5)
Number of subjects: 24
Study: 8489107

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 500 mg/kg weekly
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 170
Study: 3829912

Group type: EXPERIMENTAL
Intervention: Ranitidine HCl 150 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cimetidine HCl 400 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31930944

Group type: EXPERIMENTAL
Intervention: Regenerated oxidised cellulose dressing (Surgicel, Ethicon, LLC, Puerto Rico)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Calcium alginate dressing (Biatain, Coloplast A/S, Denmark)
Number of subjects: 24
Study: 28926413

Group type: EXPERIMENTAL
Intervention: Cognitive content measures (catastrophizing and self-efficacy)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cognitive process measure (mindfulness)
Number of subjects: 165
Study: 27560291

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser pretreatment followed by autologous transplantation and phototherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Autologous transplantation and phototherapy alone
Number of subjects: 20
Study: 25008873

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed protein formula (eHF) for 10-14 days after birth, then standard preterm formula (SPF) until discharge (for infants <32 weeks gestational age)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Standard preterm formula (SPF) initially, switched to eHF (7-14 days) if feeding intolerance at 6-8 days after birth (for infants 32-34 weeks gestational age)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Standard preterm formula (SPF)
Number of subjects: 328
Study: 22126591

Group type: EXPERIMENTAL
Intervention: PRF-BPBM
Number of subjects: 17

Group type: COMPARATOR
Intervention: PRF
Number of subjects: 17
Study: 20352149

Group type: EXPERIMENTAL
Intervention: Rabeprazole alone (group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrotalcite alone (group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rabeprazole combined with hydrotalcite (group D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation (group A)
Number of subjects: 0
Study: 18317187

Group type: EXPERIMENTAL
Intervention: Discectomy followed by fusion with a Ray titanium cage
Number of subjects: 86

Group type: COMPARATOR
Intervention: Discectomy alone
Number of subjects: 86
Study: 17041689

Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 50

Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 50
Study: 14570681

Group type: EXPERIMENTAL
Intervention: Controlled hypotension with minimal inflation pressures (CHAMIP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normotensive anesthesia and conventional inflation pressures
Number of subjects: 36
Study: 10917986

Group type: EXPERIMENTAL
Intervention: Saphenous vein (SV)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Human umbilical vein (HUV)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE)
Number of subjects: 752

Group type: COMPARATOR
Intervention: HUV
Number of subjects: 752

Group type: COMPARATOR
Intervention: PTFE
Number of subjects: 752
Study: 8665202

Group type: EXPERIMENTAL
Intervention: Colonic pouch anastomosis (n=14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Straight anastomosis (n=16)
Number of subjects: 30
Study: 1572123

Group type: EXPERIMENTAL
Intervention: Oral tetrahydroaminoacridine (THA) and lecithin (75 to 200mg per day)
Number of subjects: 6
Study: 2865021

Group type: EXPERIMENTAL
Intervention: Somatostatin intravenous infusion
Number of subjects: 6
Study: 30449234

Group type: EXPERIMENTAL
Intervention: AR101 (peanut-derived investigational biologic oral immunotherapy)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: AR101
Number of subjects: 496
Study: 28372591

Group type: EXPERIMENTAL
Intervention: Cooperation between geriatricians and general practitioners involving clinical geriatric assessment, medication review, and clinical follow-up over 24 weeks.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cooperation between geriatricians and general practitioners
Number of subjects: 200
Study: 26106623

Group type: EXPERIMENTAL
Intervention: Insulin sensitizing medications (thiazolidinediones and metformin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin provision strategy (insulin and/or sulfonylureas)
Number of subjects: 0
Study: 22998439

Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cancellous Screws
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combined outcomes
Number of subjects: 62
Study: 20878571

Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy (Group A, n=22)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (Group B, n=21)
Number of subjects: 43
Study: 18446859

Group type: EXPERIMENTAL
Intervention: Dengue virus infection
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16174116

Group type: EXPERIMENTAL
Intervention: Regular hemodialysis (H/D)
Number of subjects: 93
Study: 12590785

Group type: EXPERIMENTAL
Intervention: Clindamycin intravaginally for three days
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo intravaginally
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Clindamycin intravaginally
Number of subjects: 388
Study: 10535337

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 23

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 23
Study: 8568137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol 400 micrograms/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol 800 micrograms/day
Number of subjects: 10
Study: 1800388

Group type: EXPERIMENTAL
Intervention: 12-hour overnight application of mepindolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 24-hour application of mepindolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both application schemes (12-hour and 24-hour)
Number of subjects: 10
Study: 6316120

Group type: EXPERIMENTAL
Intervention: Levamisole as an adjunct to chemotherapy and radiotherapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo as an adjunct to chemotherapy and radiotherapy
Number of subjects: 13
Study: 29660046

Group type: EXPERIMENTAL
Intervention: Optometrists assessing smoking status
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Optometrists advising smokers to quit
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Optometrists offering assistance via referral
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Optometrists providing advice on smoking cessation medications
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Perceived barriers to intervention delivery
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Assessment and advising likelihood based on practice location and training
Number of subjects: 408
Study: 30132252

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide 35% (G1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Carbamide peroxide 37% (G2)
Number of subjects: 50
Study: 27013060

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid (with or without 180 mg loading dose)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid (with loading dose)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid (without loading dose)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Prasugrel 10 mg QD
Number of subjects: 82
Study: 24759300

Group type: EXPERIMENTAL
Intervention: Spot urine phosphate-to-creatinine ratio
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: New predictive equation including spot urine phosphate, creatinine, age, sex, and weight
Number of subjects: 143
Study: 22242162

Group type: EXPERIMENTAL
Intervention: gag DNA alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: gag DNA + IL-15
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: gag DNA + high dose (1500 ug) IL-12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: gag DNA + intermediate dose (500 ug) IL-12
Number of subjects: 0
Study: 19643320

Group type: EXPERIMENTAL
Intervention: Atorvastatin reload (80 mg 12 h before intervention, with a further 40-mg pre-procedural dose)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Atorvastatin reload
Number of subjects: 383
Study: 17463217

Group type: COMPARATOR
Intervention: Indomethacin alone for 5 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Estradiol/drospirenone alone for 12 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Estradiol/drospirenone plus indomethacin for 5 days
Number of subjects: 32
Study: 15264655

Group type: EXPERIMENTAL
Intervention: Indirect group I (Therma Cure laboratory resin and Custom IQ resin)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Indirect group II (Transbond XT and Sondhi Rapid Set)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Direct-bonding group (Transbond XT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: In vivo evaluation using Sondhi's indirect-bonding resin
Number of subjects: 60

Group type: COMPARATOR
Intervention: In vivo evaluation using Therma Cure and Custom IQ
Number of subjects: 60
Study: 12074455

Group type: EXPERIMENTAL
Intervention: Ball-attachment dentures
Number of subjects: 64

Group type: COMPARATOR
Intervention: Bar-clip dentures
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both types of IOD
Number of subjects: 64
Study: 11313190

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Oral‐B‐7 EB 5 K, Braun AG, Kronberg, Germany)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Oral‐B, Power Tip, Braun AG, Kronberg, Germany)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (received instructions only once a year)
Number of subjects: 50
Study: 9407819

Group type: EXPERIMENTAL
Intervention: Policy for standardizing care of patients paralyzed with NMBAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational tool (policy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NMBA order form
Number of subjects: 0